Diagnosis and treatment of CMV and EBV Reactivation as well as Post-transplant Lymphoproliferative Disorders following Allogeneic Stem Cell Transplantation: An SFGM-TC report

Pathologie Biologie

Volumn 61, Issue 4, 2013, Pages 152-154

  Bay, J O ^a   Peffault de Latour, R ^b   Bruno, B ^c   Coiteux, V ^c   Guillaume, T ^d   Hicheri, Y ^e   Paillard, C ^f   Suarez, F ^g   Turlure, P ^h   Alain, S ^h   Bulabois, C E ⁱ   Socie G ^b   Bauters, F ^c   Yakoub Agha, I ^c  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b France Greffe de Moelle   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g HÔpital Necker   (France)

^h DUPUYTREN UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL MICHALLON   (France)

Author keywords

Allogeneic stem cell transplantation; CMV; EBV

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL PRACTICE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; LYMPHOPROLIFERATIVE DISEASE; MEDICAL SOCIETY; NONHUMAN; VIRUS REACTIVATION; ALLOGREFFE DE CELLULES SOUCHES HÉMATOPOÏÉTIQUES; ALLOTRANSPLANTATION; CMV; DONOR SELECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PHYSIOLOGIC MONITORING; PHYSIOLOGY; PRACTICE GUIDELINE; PRIMARY PREVENTION; STANDARD; UTILIZATION REVIEW; VIRUS ACTIVATION;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGREFFE DE CELLULES SOUCHES HÉMATOPOÏÉTIQUES; CMV; EBV;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DONOR SELECTION; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; LYMPHOPROLIFERATIVE DISORDERS; MONITORING, PHYSIOLOGIC; PRIMARY PREVENTION; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 84884538229     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2013.07.003     Document Type: Article

References (4)

1. Thiele T., et al. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 2011, 51(12):2620-2626.
2. Pietersma F.L., et al. Influence of donor cytomegalovirus (CMV) status on severity of viral reactivation after allogeneic stem cell transplantation in CMV-seropositive recipients. Clin Infect Dis 2011, 52(7):e144-e148.
3. Heslop H.E. How I treat EBV lymphoproliferation. Blood 2009, 114(19):4002-4008.
4. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113(23):5711-5719.